Received Nov 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
non responder to first series; This non-serious case was reported by a consumer via call center representative and described the occurrence of therapy non-responder in a patient who received HBV (Engerix B) for prophylaxis. On an unknown date, the patient received Engerix B. On an unknown date, an unknown time after receiving Engerix B, the patient experienced therapy non-responder (Verbatim: non responder to first series). The outcome of the therapy non-responder was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date 28 OCT 2025: The patient who was a non responder to Engerix-B. They were wondering what the recommendation for dosing would be/ if they repeat the series when this happened. The batch number was not provided upon follow- up with the reporter.
Test Name: Hepatitis B antibody; Result Unstructured Data: (Test Result:Negative,Unit:unknown,Normal Low:,Normal High:)